Search

Claes O Bavik

from Shoreline, WA
Age ~65
Get Report
Also known as:
Claes Kristina Bavik, Claes Kristma Bavik, Claes Olof Bavik, Claes O Babi, Claes O Bavick, Abiu B Claes, Bavik Claes, Claes K
Phone and address:
1706 NE 179Th St APT 302, Seattle, WA 98155
(206) 363-0169
Related to:
Kristin T Ames, 60Sierra J Bavik, 24Linnea M Bavik, 29Dawn E Walter, 73K Bavik, 60Richard E Ames, 86Sean Bavik, 60Jessie W Ames, 64Richard K Ames, 57Hiroco C Ames, 63
Connected to:
James E Bavin, 50John H Bavin, 73Robin L Bavin, 56William M Bavin, 51Josephine A Bavineau, 72Aruna Bavineni, 69Dean Bavington, 50Prathap Bavirisetty, 44Lance C Bavis, 70

Claes Bavik Phones & Addresses

  • 1706 NE 179Th St APT 302, Seattle, WA 98155 (206) 363-0169
  • 20216 41St St, Seattle, WA 98155 (206) 363-0169
  • Shoreline, WA
  • Mountlake Terrace, WA
  • Austin, TX
  • Nashville, TN

Resumes

Resumes

Claes Bavik Photo 1

Consultant

View page
Location:
Seattle, WA
Industry:
Computer Games
Work:
Blueprint Consulting Services
Consultant
Acucela Inc. Aug 2005 - Dec 2013
Associate Director, Biology | Head of Research
Fred Hutch 2003 - 2005
Postdoctoral Research Fellow | Oncology
University of Sheffield Molecular Skincare 2000 - 2002
Senior Research Fellow and Chief Science Officer
The University of Texas at Austin 1997 - 2000
Assistant Professor
Education:
University of Washington - Michael G. Foster School of Business 2003 - 2003
University of Sheffield 2002
Vanderbilt University 1995 - 1997
Karolinska Institutet 1985 - 1992
Doctorates, Doctor of Philosophy, Biochemistry, Philosophy, Chemistry Lund University 1980 - 1985
Bachelors, Bachelor of Science, Biology Scripps Research
Lund University
Bachelors University of Washington
Skills:
Drug Discovery
Biotechnology
Pharmacology
Molecular Biology
Drug Development
Assay Development
Clinical Development
Clinical Trials
In Vitro
Protein Chemistry
Cell
Ophthalmology
Research
Oncology
Regulatory Submissions
Management
In Vivo Pharmacology
In Vitro Pharmacology
Business Development
Fitness Instruction
Technical Translation
Localization
Software Testing
Interests:
Kyokushinkai Karate Instructor (2Nd Dan)
Health
Languages:
English
Swedish
French
Claes Bavik Photo 2

Principal

View page
Location:
Seattle, WA
Work:
Shapeguard
Principal
Interests:
Kyokushinkai Karate Instructor (2Nd Dan)

Business Records

Name / Title
Company / Classification
Phones & Addresses
Claes Bavik
Assistant Director Biology
Acucela Inc.
Biotechnology · Commercial Physical Research
1301 2 Ave SUITE 4200, Seattle, WA 98101
21720 23 Dr SE, Bothell, WA 98021
(425) 527-3260, (206) 805-8300, (206) 805-8301, (425) 527-3156

Publications

Us Patents

Enzyme Inhibitors For Inactivating Allergens

View page
US Patent:
20040248769, Dec 9, 2004
Filed:
Feb 20, 2004
Appl. No.:
10/487657
Inventors:
Claes Bavik - Seattle WA, US
Michael Cork - Sheffield, GB
Birgit Helm - Sheffield, GB
David Buttle - Sheffield, GB
International Classification:
A61K038/56
US Classification:
514/002000
Abstract:
The inventive concept relates to the inactivation of allergens using inhibitors for hydrolytic enzymes, and preferably proteases. Embraced within the overall inventive concept is the use of hydrolytic enzyme inhibitors for manufacture of medicaments for the prophylactic treatment of allergic conditions, and formulations for their use. Also, there is included a method for the manufacture of air treatment devices with the enzyme inhibitor bound to the surface of the support material such as an air filter. There is also a formulation containing the enzyme inhibitors for inactivating allergenic residues on fabrics or carpets.

Diagnosis And Treatment Of Disease

View page
US Patent:
20080292615, Nov 27, 2008
Filed:
Jan 17, 2008
Appl. No.:
12/016012
Inventors:
Rachid Tazi-Ahnini - Sheffield, GB
Claes Bavik - Seattle WA, US
Simon Ward - Sheffield, GB
Gordon Duff - Sheffield, GB
Michael Cork - Derbyshire, GB
Assignee:
MOLECULAR SKINCARE LIMITED - Cambridge
International Classification:
A61K 39/395
A61K 31/711
A61K 38/08
A61P 11/06
A61P 17/00
A61K 38/02
US Classification:
4241301, 514 44, 514 2, 514 17
Abstract:
We disclose a method of diagnosis of a disease, or susceptibility to a disease associated with abnormal cell-cell adhesion between epithelial cells, the method comprising detection of a mutation in a nucleic acid encoding an adhesion protein, a protease, or a protease inhibitor of an individual. Methods of making medicaments and methods of treatment and/or prophylaxis are also disclosed.

Pharmacology Of Visual Cycle Modulators

View page
US Patent:
20110003895, Jan 6, 2011
Filed:
Jul 2, 2010
Appl. No.:
12/830155
Inventors:
Ryo Kubota - Seattle WA, US
Nancy Boman - Bothell WA, US
Claes Bavik - Bothell WA, US
Ian L. Scott - Monroe WA, US
Assignee:
ACUCELA, INC. - Bothell WA
International Classification:
A61K 31/19
A61K 31/135
A61B 5/0496
US Classification:
514570, 514653, 600558
Abstract:
Described herein are methods for the treatment of an ophthalmic disease or disorder comprising the administration of non-retinoid visual cycle modulators.

Diagnosis And Treatment Of Disease

View page
US Patent:
20040106120, Jun 3, 2004
Filed:
Nov 5, 2003
Appl. No.:
10/433234
Inventors:
Rachid Tazi-Ahnini - Sheffield, GB
Claes Bavik - Seattle WA, US
Simon Ward - Sheffield, GB
Gordon Duff - Sheffield, GB
Michael Cork - Derbyshire, GB
International Classification:
C12Q001/68
US Classification:
435/006000
Abstract:
We disclose a method of diagnosis of a disease, or susceptibility to a disease associated with abnormal cell-cell adhesion between epithelial cells, the method comprising detection of a mutation in a nucleic acid encoding an adhesion protein, a protease, or a protease inhibitor of an individual.

Pharmacology Of Visual Cycle Modulators

View page
US Patent:
20200188336, Jun 18, 2020
Filed:
Oct 25, 2019
Appl. No.:
16/664179
Inventors:
- Seattle WA, US
Nancy BOMAN - Seattle WA, US
Claes BAVIK - Seattle WA, US
Ian L. SCOTT - Seattle WA, US
International Classification:
A61K 31/166
A61K 31/137
A61K 31/135
A61K 9/00
A61K 9/50
A61K 31/19
A61K 31/195
Abstract:
Described herein are methods for the treatment of an ophthalmic disease or disorder comprising the administration of non-retinoid visual cycle modulators.
Control profile
Claes O Bavik from Shoreline, WA, age ~65 Get Report